

# Atherosclerosis - Pipeline Insight, 2021

<https://marketpublishers.com/r/A3B902025EC0EN.html>

Date: May 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: A3B902025EC0EN

## Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Atherosclerosis – Pipeline Insight, 2021," report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Atherosclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Atherosclerosis Understanding

#### Atherosclerosis: Overview

Plaque (fatty deposits) build up in arteries is called atherosclerosis. These deposits are made up of cholesterol, fatty substances, cellular waste products, calcium and fibrin (a clotting material in the blood). As plaque builds up, the wall of the blood vessel thickens. This narrows the channel within the artery – reducing blood flow. Atherosclerosis is a slow, lifelong progression of changes in the blood vessels that may start in childhood and get worse faster with the age. Atherosclerosis usually doesn't cause any symptoms until blood supply to an organ is reduced. When this happens, symptoms vary, depending on the specific organ involved: Heart — Symptoms include the chest pain of angina and shortness of breath, sweating, nausea, dizziness or light-headedness, breathlessness or palpitations. Brain — When atherosclerosis narrows brain arteries, it

can cause dizziness or confusion; weakness or paralysis on one side of the body. Abdomen — When atherosclerosis narrows the arteries to the intestines, there may be dull or cramping pain in the middle of the abdomen. There is no cure for atherosclerosis, but treatment can slow or halt the worsening of the disease. The major treatment goal is to prevent significant narrowing of the arteries so that symptoms never develop and vital organs are never damaged.

'Atherosclerosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atherosclerosis pipeline landscape is provided which includes the disease overview and Atherosclerosis treatment guidelines. The assessment part of the report embraces, in depth Atherosclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atherosclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Atherosclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Atherosclerosis.

## Atherosclerosis Emerging Drugs Chapters

This segment of the Atherosclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Atherosclerosis Emerging Drugs

### Aloricumab: Sanofi/ Regeneron

Alirocumab is a fully-human monoclonal antibody targeting proprotein convertase subtilisin kexin type 9 (PCSK9) that is being co-developed by Regeneron. Amgen loses

appeal in patent suit against Sanofi/Regeneron's Praluent. Amgen loses appeal in patent suit against Sanofi/Regeneron's Praluent. The drug is in registration phase for the treatment of patients with Atherosclerosis.

### VB 201: VBL therapeutics

The lead drug from the lecinoxoids platform, VB-201, is an oral small molecule. VB 201 is an immune-response modifier that acts by reducing the chemokine-mediated migration of monocytes to the damaged organ. The drug is currently in Phase II stage of development for the treatment of patients with Atherosclerosis.

Further product details are provided in the report

### Atherosclerosis: Therapeutic Assessment

This segment of the report provides insights about the different Atherosclerosis drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Atherosclerosis

There are approx. 25+ key companies which are developing the therapies for Atherosclerosis. The companies which have their Atherosclerosis drug candidates in the most advanced stage, i.e. Registration include, Sanofi/ Regeneron.

#### Phases

DelveInsight's report covers around 25+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Atherosclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

### Atherosclerosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atherosclerosis therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atherosclerosis drugs.

### Atherosclerosis Report Insights

Atherosclerosis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### Atherosclerosis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

### Key Questions

## Current Treatment Scenario and Emerging Therapies:

How many companies are developing Atherosclerosis drugs?

How many Atherosclerosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atherosclerosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atherosclerosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Atherosclerosis and their status?

What are the key designations that have been granted to the emerging drugs?

## Contents

Introduction

Executive Summary

Atherosclerosis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Atherosclerosis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Atherosclerosis companies' collaborations, Licensing, Acquisition -Deal Value Trends

Atherosclerosis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Registered)

Comparative Analysis

Aloricumab: Sanofi/ Regeneron

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

VB 201: VBL therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early stage products (Phase I)

Comparative Analysis

BT 200: Band Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Atherosclerosis Key Companies

Atherosclerosis Key Products

Atherosclerosis- Unmet Needs

Atherosclerosis- Market Drivers and Barriers

Atherosclerosis- Future Perspectives and Conclusion

Atherosclerosis Analyst Views

Atherosclerosis Key Companies

Appendix



## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Atherosclerosis
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Atherosclerosis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Atherosclerosis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/A3B902025EC0EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A3B902025EC0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970